Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elamipretide Extension in Primary Mitochondrial Myopathy
NCT02976038Phase 2Terminated
- Sponsor
- Stealth BioTherapeutics
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elamipretide in primary mitochondrial myopathy (PMM), sponsored by Stealth BioTherapeutics. Primary endpoint: 6 Minute Walk Test. Started Dec 2016; status: terminated.
02
Drugs
elamipretide
03
Conditions
primary mitochondrial myopathy (PMM)
Beyond the preview
Go deeper on NCT02976038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976038.